BNTC Benitec Biopharma Inc. Insider Trading

Suvretta Capital acquires 144,223 shares at $12.85–$13.44 in 6 transactions, raising stake to 1.85M shares (+8.5%)

Suvretta Capital Management, LLC executed 6 separate purchases totaling 144,223 shares for $1,903,132.88 between December 23 and December 29, 2025, at a blended average price of $13.20. The current price of $13.49 is -19.6% from the 52-week high of $16.79, placing the stock in the lower half of its annual trading range. Suvretta's holding increased 8.5% to 1.85M shares post-transaction. The company reported zero latest-quarter revenue and a net loss of -$8,965,000.00, with annual revenue decline of -100.0%, indicating Benitec remains unprofitable. Across Suvretta's cross-ticker track record, prior buys averaged +4.9% 30-day return and +15.7% 90-day return with a 66.67% win rate, but five recent BNTC trades (December 18–22) have no measurable outcomes yet, preventing assessment of Suvretta's execution accuracy at this specific ticker.

SUVRETTA CAPITAL MANAGEMENT buys 46,141 shares for $538,972.28 at blended avg $11.68; holdings now 1,826,653 shares.

Director SUVRETTA CAPITAL MANAGEMENT made 6 separate purchases totaling 46,141 shares for $538,972.28 over three trading days (Dec 18-22), lifting holdings from 1.78M to 1.83M shares (+2.6%). At BNTC specifically, the prior 3 measurable buy transactions all showed negative 90-day returns (-14.2%, -14.2%, -10.1%), indicating timing challenges at this ticker. The company reports zero latest-quarter revenue and a $-9.0M net loss, with annual revenue declining -100.0%, creating a high-risk profile. Current stock price ($12.35) is -26.4% from its 52-week high and down -6.9% over the last 30 days, yet the director's blended purchase price of $11.68 was executed into that weakness. While this insider's broader track record across all tickers shows 75.00% win rate over 90 days (+15.0% average return), execution at this specific ticker has not materialized into gains, and the company's fundamental deterioration demands scrutiny of whether the purchase reflects genuine conviction or exposure to deteriorating business conditions.

Director Suvretta Capital purchases 1,481,481 shares at $13.50 for $19,999,993.50, raising stake 437.9% to 1,819,812 shares

Suvretta Capital, as a director, executed 2 separate transactions totaling 1,481,481 shares for $19,999,993.50 ($20.0M), substantially increasing its position from 338,331 shares to 1,819,812 shares at a blended average price of $13.50. The current price of $12.89 sits 23.2% below the 52-week high and 13.6% lower over the past 30 days, positioning this purchase below recent highs. However, at BNTC specifically, Suvretta's prior buy timing has been inconsistent: only 1 of 5 prior trades showed a positive 90-day return (+15.2%), while the other four posted losses ranging from -10.1% to -14.2% over 90 days. The company's fundamentals present a concern: zero quarterly revenue and $-9,354,000.00 net income for the latest quarter, with annual revenue contracting 100.0% year-over-year, indicating a pre-revenue or severely distressed operational state. This substantial $20.0M capital commitment by a major director into an unprofitable, revenue-depleted entity merits close examination of the strategic rationale and timing.

Director Suvretta Capital purchased 16,497 shares at blended $12.83 on 2025-03-31 for $211,736.04; 3 of 3 prior same-ticker buys showed strong 90d returns.

Suvretta Capital Management, LLC (Director) executed 4 separate purchases totaling 16,497 shares for $211,736.04, expanding holdings from 1.05M to 1.07M shares (+1.6%) at a blended average price of $12.83 on 2025-03-31. The insiders's prior open-market track record across all tickers shows strong cross-ticker performance (12 prior buys, 100.00% 90-day win rate, avg 90d return +25.9%). More notably at BNTC specifically, all 3 prior measurable same-ticker buys (2025-03-26 and 2024-12-23/24) achieved positive 90-day returns, ranging from +27.5% to +46.7%, indicating a consistent pattern of well-timed entry points at this ticker. The company remains unprofitable (net income $-7,357,000.00 most recent full year) with zero revenue in the latest quarter, but the insider's historical accuracy at accumulation points warrants investor monitoring of whether current purchasing patterns precede similar near-term gains.

Suvretta Capital bought 900,000 shares (900.0K) at $13.00 on 2025-03-26, bringing stake to 1,066,764 shares (+539.7%)

Suvretta Capital, a director at Benitec Biopharma, executed 2 separate purchases totaling 900,000 shares for $11,700,000.00 on 2025-03-26, expanding its position by 539.7% to 1,066,764 shares. The scale of the accumulation—a nine-figure commitment at $13.00 per share—represents a major capital deployment into the stock. The insider's track record at BNTC spans 5 prior buys, all of which achieved positive 90-day returns, with the most recent prior purchase (2024-12-03) yielding +29.4% over 90 days; the cross-ticker track record shows 10 prior buys with a 100.00% 90-day win rate and an average 90d return of +25.9%. The current price of $13.43 remains within the stock's 52-week range and shows strong momentum (+24.8% over 30 days and +11.9% over 90 days), though still 20.0% below the 52-week high. Investors should note that the company reported zero latest-quarter revenue and a net loss of $-7,357,000.00, with annual revenue declining -100.0%, underlining that this accumulation occurs in a fundamentally unprofitable, pre-revenue stage context.

Suvretta Capital Management buys 47.5K shares at blended $11.09, raising stake to 960.6K; stock up 30% in 90 days.

Suvretta Capital Management, a director at Benitec Biopharma, executed 4 separate purchases totaling 47,520 shares for $527,174.46 at a blended average price of $11.09 on December 23–24, 2024, increasing its holding by 5.2% to 960,554 shares. The purchases occur after the stock has appreciated 30.0% over 90 days and 21.8% over 30 days from the current price of $12.00. Prior transactions by this insider at BNTC over the past month have delivered positive 30-day returns ranging from 11.6% to 25.1%, though the company remains unprofitable with recent quarterly revenue at $0.00 and annual net income of $-5,059,000.00. The timing of this accumulation follows sustained price momentum, and the insider's cross-ticker track record shows an average 30-day return of 18.4% on 6 prior buys, establishing a pattern of purchases made during upward price movement.

Suvretta Capital Management bought 42,000 shares of BNTC at $9.60 in 2 transactions (12/3/2024), raising stake to 955.1K shares

Suvretta Capital Management filed 2 separate purchases totaling 42,000 shares for $403,200.00 at $9.60 per share on 2024-12-03, expanding its position from 913.1K to 955.1K shares (+4.6%). The timing reflects recent buying activity—the insider executed 4 prior trades at BNTC on 2024-11-19 and 2024-11-20, all purchases. At $9.60, the transaction price sits below the current price of $9.78 but well below the 52-week high of $11.48. Critically, the company is unprofitable (net income of $-5.1M in the latest full year) with zero revenue in the latest quarter and -100.0% annual revenue growth, presenting a materially challenged operating environment. The accumulation pattern (multiple buys within days) in a loss-making, revenue-free company warrants investor scrutiny of the underlying business rationale.

Suvretta Capital director purchases 41,436 shares at $10.05 average (4 txns totaling $416.6K) as BNTC stock down 4.6% in 30 days

Suvretta Capital Management, LLC executed four separate purchases totaling 41,436 shares for $416,615.92, increasing holdings by 4.6% to 950,314 shares post-transaction. The blended average price of $10.05 sits near the current price of $10.20, and the timing coincides with a 30-day decline of 4.6%, though the stock remains up 12.7% over 90 days from a 52-week low of $2.80. The company is unprofitable with net income of $-5,059,000.00 for its most recent full fiscal year and zero revenue in the latest quarter, placing this acquisition in the context of a pre-revenue or early-stage biotech entity. The director's continued accumulation in an unprofitable company undergoing significant operational challenges warrants attention to any forward-looking disclosures or catalysts that may inform the investment thesis.